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Abstract: Macrophages are important target cells for HIV-1 infection that play significant 
roles in the maintenance of viral reservoirs and other aspects of pathogenesis. 
Understanding the determinants of HIV-1 tropism for macrophages will inform HIV-1 
control and eradication strategies. Tropism for macrophages is both qualitative (infection 
or not) and quantitative (replication capacity). For example many R5 HIV-1 isolates cannot 
infect macrophages, but for those that can the macrophage replication capacity can vary by 
up to 1000-fold. Some X4 viruses are also capable of replication in macrophages, 
indicating that cellular tropism is partially independent of co-receptor preference. 
Preliminary data obtained with a small number of transmitted/founder viruses indicate 
inefficient macrophage infection, whereas isolates from later in disease are more frequently 
tropic for macrophages. Thus tropism may evolve over time, and more macrophage tropic 
viruses may be implicated in the pathogenesis of advanced HIV-1 infection. 
Compartmentalization of macrophage-tropic brain-derived envelope glycoproteins (Envs), 
and non-macrophage tropic non-neural tissue-derived Envs points to adaptation of HIV-1 
quasi-species in distinct tissue microenvironments. Mutations within and adjacent to the 
Env-CD4 binding site have been identified that determine macrophage tropism at the entry 
level, but post-entry molecular determinants of macrophage replication capacity involving 
HIV-1 accessory proteins need further definition. 
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1. Introduction 
Macrophages are long-lived, terminally-differentiated tissue-resident cells capable of limited 
replication, that are phenotypically and functionally heterogeneous [1,2]. As innate immune sentinel 
phagocytes, their role involves clearance of pathogens, apoptotic cells and debris, and antigen 
presentation to T cells [1,2]. Macrophages are also important in HIV-1 pathogenesis. Infected 
macrophages in the brain are central to the development of HIV-1-associated neurological disorders 
(HAND) [3]. Macrophages remain productively infected by HIV-1, often without obvious cytopathic 
effects, forming long-lived virus reservoirs [4] with the potential to transmit HIV-1 to activated CD4+ 
T cells during cell-to-cell interactions [5,6]. Better understanding of macrophage tropism is therefore 
highly relevant to the design of strategies to reduce HIV-1 persistence and spread, and to eradicate 
viral reservoirs. Macrophage tropism is a feature conserved across lentivirus species [7]. The term 
tropism is principally used to define the target cell preference of the virus, although is frequently also 
used to describe chemokine co-receptor usage of HIV-1 [8]. 
The process of HIV-1 entry into macrophages has been well studied. C-type lectins [9], 
integrins [10] and heparan sulfate proteoglycans [11] may initially bind HIV-1, allowing subsequent 
engagement of CD4 and a chemokine coreceptor (usually CCR5 or CXCR4) by the envelope 
glycoprotein (Env) surface subunit gp120 [8]. CD4 binding induces a conformational change in gp120 
that exposes the co-receptor binding site, and the co-receptor-gp120 interaction destabilizes the Env 
spike and triggers gp41-mediated membrane fusion [8]. Fusion may occur at the cell membrane or 
from within macropinocytic [12] or endosomal [13] vesicles.  
Macrophage replication capacity of CCR5-using (R5) virus isolates can vary by up to 1000-fold 
in vitro, and many primary R5 isolates and most CXCR4-using (X4) isolates are unable to replicate in 
macrophages [14,15]. Thus the concept of tropism is both categorical (replication or not), and 
continuous (the spectrum of replication capacity). In the absence of a satisfactory definition of 
macrophage tropism in the literature, we define as macrophage tropic (mac-tropic), viruses capable of 
infecting macrophages in vitro in single-cycle or spreading infection assays using monocyte-derived 
macrophages (MDM). We consider viruses that do not replicate in single-cycle or spreading infection 
assays to be non-macrophage tropic. To conceptualise infection efficiency of mac-tropic isolates, we 
also introduce the term “macrophage replication capacity” (MRC). MRC is an arbitrary measure of 
replication depending on the assay used. Reference laboratory-adapted R5 HIV-1 isolates (including 
YU-2, BaL, and SF162) demonstrate higher MRC than most primary (‘field’) isolates or molecular 
clones obtained without amplification in vitro, and can provide a positive control for qualitative and 
relative quantitative assessment of tropism phenotypes of primary isolates. Together, the terms 
mac-tropic and MRC allow us to more clearly distinguish the complementary but distinct qualitative 
and quantitative aspects respectively of the tropism phenotype, which are often used interchangeably 
in the literature. Beyond such definitions, methodological considerations for obtaining primary viruses 
also warrant discussion in the context of tropism assessment.  
Isolation of primary virus from cultured tissue samples or donor donor peripheral blood 
mononuclear cells (PBMCs) has the potential to drive adaptation to a specific cell-type that could 
confound assessment of the tropism phenotype, and may also select for viruses with more rapid in vitro 
replication kinetics that do not represent the dominant species in vivo. Bulk or limiting dilution PCR Viruses 2011, 3  
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amplification of full-length molecular clones or env sequences avoids these issues, but is subject to taq 
polymerase errors (either mutations or recombination) as well as template resampling or bias in 
amplification due to primer selection [16]. These issues can be overcome by single genome 
amplification and sequencing (SGA) from a single template [17], although to date most studies have 
employed PBMC co-culture or bulk PCR amplification of env sequences. 
The  in vivo tropism of HIV-1 is understandably difficult to assess directly. Interpretation 
of  surrogate markers of productive infection such as detection of proviral DNA in circulating 
monocytes  [18] and tissue macrophages [19–21] can be confounded by host restriction factors, 
including those operating at the post-integration stage that regulate latency, as well as tissue-specific 
differences in macrophage HIV-1 permissiveness (see Section 5). Since intrinsic macrophage 
restriction factors for HIV-1 have been recently reviewed [22,23], we will focus here on the viral 
determinants of tropism at the entry and post-entry levels. 
2. Beyond Co-Receptor Usage 
HIV-1 tropism classification systems have gone through several iterations over the years (reviewed 
in [24]). When the principal co-receptors for HIV-1 were initially identified, it appeared that viral 
tropism for macrophages and R5 co-receptor preference, were closely correlated. Although this is 
generally the case, there are exceptions (reviewed in [24]); for example, it was noted that some 
CXCR4-using (X4) viruses could productively infect macrophages [25,26], whilst many R5 isolates 
could not [15], therefore indicating that the tropism phenotype is related to, but distinct from, 
co-receptor preference. A reasonable proposal to modify the co-receptor classification to incorporate 
macrophage tropism [24] has not been widely adopted; for clarity in this review we qualify cellular 
tropism alongside viral co-receptor preference. 
3. Association with Disease Stage 
Up to 50% of patients who progress to AIDS do so with a viral quasispecies that has switched 
co-receptor preference from R5 to X4 [24]. The remainder of individuals progress to AIDS without 
co-receptor switching, retaining the CCR5 preference of the initial transmitted virus(es). In these 
individuals the mac-tropism of R5 isolates amplified by PBMC co-culture has been associated with 
disease stage in cross-sectional studies [27,28]. R5 isolates from individuals with advanced HIV-1 
infection or AIDS can display enhanced in vitro MRC compared to early infection isolates [27,28]. It 
is unclear whether this apparent association with disease progression may result from evolution of 
tropism with time, perhaps to counter progressive loss of target CD4+ T cells [29], or whether 
macrophage replication is a direct viral virulence mechanism in its own right [30]. Although only one 
study [31] has been specifically designed with the principal aim of assessing the dynamics of tropism 
with time, other longitudinal studies have provided further support for the proposed association 
between disease stage and mac-tropism/MRC for R5 isolates observed in cross-sectional studies [31–33]. 
Richards and colleagues [31] examined changes in R5 mac-tropism and MRC over time of clade B 
Envs amplified by PCR from proviral DNA or viral RNA in three subjects. Isolates were obtained 
periodically from the first 3 weeks to several years post-infection. The env sequences were cloned into 
an isogenic replication competent virus backbone. A highly divergent tropism phenotype was observed Viruses 2011, 3  
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for early infection Envs, which may at least in part relate to the non-SGA method of sampling, which 
is prone to taq polymerase errors (see above). Clones from later stages of infection were more 
frequently mac-tropic, and in 2/3 subjects all late-stage clones were mac-tropic. In one subject who 
progressed to AIDS, MRC was highest at the time of AIDS diagnosis. Similarly Mascriota and 
colleagues [32] measured the in vitro tropism phenotype of primary isolates acquired longitudinally 
(ranging from 3–5 isolates) from 13 individuals by PBMC co-culture. Although the exact time of 
seroconversion was unknown, these patients were clinically classified as rapid, late or long-term 
non-progressors (LTNP) based on CD4+ T cell count and time to AIDS. The authors hypothesized that 
mac-tropism would decline over time in progressors. This hypothesis was discounted, but insufficient 
data were presented to identify whether there was, by contrast, a temporal increase in mac-tropism or 
MRC. A representative data plot (Figure 3 in [32]) with two subjects per group was presented. 
Consistent with the alternative hypothesis that mac-tropism increases with disease progression, most 
isolates from late or rapid progressors were mac-tropic. By contrast, 4/5 of the non-mac-tropic isolates 
were obtained from LTNP. There was also an increase in MRC over time in 1/2 rapid and late 
progressors, but no change in 2/2 LTNP. Finally, Etemad and colleagues [33] amplified the V1-V5 
region of clade A envs by PCR from PBMC in early and chronic infection (from 8 subjects) and cloned 
these into an isogenic clade A nef-deleted replication competent backbone, and tested MRC. No 
consistent patterns were observed, which may possibly relate to the earlier disease stage of the chronic 
isolates (median 41 months post-seroconversion) tested here in comparison to other studies, or to the 
absence of nef (see Section 8). In 3/8 subjects, chronic isolates replicated more efficiently than early 
isolates, whilst in 4/8, no clear increase was seen. In 1/8 a decrease in MRC was observed. However 
the data from this individual may have been biased by the brief sampling interval between isolates 
(early isolate—6 months, chronic isolate—24 months) and the availability of only a single chronic 
isolate for comparative testing.  
Overall, it appears that more isolates from individuals with advanced HIV-1 or AIDS are 
mac-tropic, and demonstrate higher MRC than earlier isolates [27,28,31], supporting the concept that 
tropism for macrophages evolves over time. However, the prospects for future prospective studies 
from early to advanced infection, which are required in order to better understand the dynamics of 
tropism, are limited by ethical constraints and moves towards earlier initiation of anti-retroviral 
therapy (ART) in chronic infection.  
The selection pressures on viral populations in vivo that may influence this evolution in tropism are 
incompletely understood. CD4+ T cell attrition and associated B cell dysfunction, which occur as 
disease progresses [34], may influence the neutralizing antibody (NAb) response in advanced HIV-1. 
However, Richards and colleagues [31] demonstrated that the divergent mac-tropism identified in early 
PCR amplified Envs occurred prior to the development of NAbs. Intriguingly, when examining 
samples from the latest time point, NAbs from the individual with the fewest mac-tropic Envs had the 
greatest degree of homologous neutralization activity. One could speculate that this might suggest an 
inverse relationship between mac-tropism of viral isolates and the exposure to, and activity of, NAbs 
later in disease. However, this is far from established. 
Tropism for macrophages has been proposed as a direct marker of pathogenesis in HIV-1 [30], 
although there are few in vivo data thus far in humans to support this hypothesis. In macaque models, 
increased monocyte turnover was observed in simian immunodeficiency virus (SIV) infection, and Viruses 2011, 3  
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appeared to better predict disease progression than viral load or CD4 count [35,36]. Whether increased 
turnover of bone marrow and peripheral blood monocytes occurs in response to direct monocyte cell 
death in the blood or bone marrow, monocyte repopulation of dying tissue macrophages, or increased 
monocyte recruitment in response to local tissue inflammation following microbial translocation across 
immune-depleted gastrointestinal mucosa, is unclear. It is also unclear whether increased monocyte 
turnover also occurs in HIV-1 infection, although markers of monocyte and macrophage activation 
have been identified in HIV-1 patients in several studies (reviewed in [37]). In addition, these markers 
appear to persist despite peripheral blood CD4+ T cell recovery after ART [38]. An interesting report 
of HIV-1 controllers recently identified an as yet undefined partial restriction to HIV-1 replication in 
macrophages, which occurred at the post-entry level, suggesting that host cell range may also be 
involved, to some degree, in HIV-1 control [39].  
4. Transmitted/Founder Viruses 
Early reports proposed macrophages as a principal target for transmitted virus based on the 
mac-tropic phenotype of these isolates [40,41]. Mac-tropism was also proposed to be a component of 
the genetic bottleneck observed for mucosal transmission of R5 HIV-1 [42]. However, recent data 
challenge this paradigm. Studies in macaques indicate that mucosal T cells are the earliest targets of 
transmitted virus (reviewed in [43]), and transmitted viruses with reduced numbers of N-linked 
glycosylation sites were shown to have enhanced affinity for CD4+ T cells expressing the alpha-4 
beta-7 integrin, a gut mucosal T cell homing marker [44]. Using the technique of single genome 
amplification (SGA), combined with a mathematical model of stochastic early virus evolution, 
transmitted sequences have been unequivocally proposed for diverse transmission routes of clade A-D 
viruses (reviewed in [16,45]). The SGA method involves amplification of a single template of RNA or 
proviral DNA, and provides more robust fidelity than traditional PCR amplification by avoiding taq 
polymerase errors, recombination, and template resampling (discussed above and reviewed in [16,45]). 
In 75–80% of mucosal transmissions, a single sequence (the transmitted/founder virus [T/F virus]) was 
proposed to be responsible for initiating infection [17,46,47], and this conclusion was recently 
supported by ultra-deep sequencing [48]. The remaining transmission events are initiated by a small 
number of T/F viruses, although multiple virus transmissions are significantly more frequent in the 
context of genital tract inflammation in the recipient [49], as well as by the rectal [50] or intravenous 
routes [51] of transmission. The preponderance of R5 T/F virus transmission also applies to horizontal 
infection from mother-to-child [52]. Overall these data demonstrate the genetic bottleneck at 
transmission, and implicate intact innate mucosal barriers to be of central importance in maintaining 
the bottleneck [42]. However, in conflict with the previous hypothesis that mac-tropism of T/F virus 
influences this genetic bottleneck, two studies report evidence of very low MRC of T/F viruses, testing 
three clade C [47] and one clade B [50] full-length infectious molecular clones (IMC) in MDM, 
despite equivalent replication kinetics in CD4+ T cells. Restriction at the level of entry may determine 
this phenotype, since a further two transmitted clade C Envs also tested displayed reduced MRC [53]. 
However the generality of entry dependence needs to be studied using a broader panel of Env-IMCs 
before firm conclusions can be drawn. In total, biological data on cellular tropism of only 6 full-length 
or env T/F sequences have been published to date. Unpublished data on additional clade B full-length Viruses 2011, 3  
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molecular clones appear to be consistent with these findings, finding clade B T/F full length and 
Env-chimeric infectious clones are capable of limited replication, but at a low MRC compared to 
reference strains [54]. More recent unpublished data suggest that MRC may be higher for clade D T/F 
viruses [55], implying clade-specific differences in the tropism phenotype of T/F viruses, but clearly 
this is an evolving area. Although making definitive conclusions is premature, overall these 
preliminary data suggest that cell-free T/F viruses are unlikely to efficiently infect macrophages to 
high levels early in infection, indicating that evolution of MRC occurs downstream of transmission of 
the founder sequence.  
In a further study, Isaacman-Beck and colleagues [53] found evidence of comparable mac-tropism 
but low MRC between donor and recipient clade C Envs isolated from transmitter pairs around the 
time of transmission. In agreement with studies of T/F viruses the authors concluded that transmitted 
Envs are not selected for macrophage replication, since the tropic phenotype of donor and recipient 
Envs was similar. However, the recipient env sequences were amplified (in all but two cases) without 
using SGA sequencing or a model of sequence evolution, and therefore most do not represent T/F 
viruses, but rather are comparable to the acute viruses studied by Richards and colleagues [31]. 
Moreover, spinoculation was used for in vitro infection assays, a method which enhances infection 
efficiency and has recently been implicated in enhanced CD4 and co-receptor expression due to 
cytoskeletal activation in T cells [56]. Therefore these data do not exclude the possibility of rapid 
evolution of mac-tropism from the founder sequence, but do highlight the need for acquisition of more 
phenotypic data on transmitted and early infection viruses. A major caveat of the published studies 
exploring the tropism phenotype of T/F viruses is that replication has been assessed only in MDM, 
rather than in more relevant tissue macrophages that have differential cellular permissiveness (see 
Section 5). In addition, alternative routes of macrophage infection by T/F viruses, such as cell-to-cell 
spread, which may play an important role in vivo [57], also remain unexplored.  
5. Compartmentalization 
Virus isolates from different tissue compartments demonstrate both intra- and inter-host 
mac-tropism diversity, with isolates from brain consistently demonstrating enhanced mac-tropism and 
replication capacity by comparison with isolates from other tissues such as blood and lymphoid tissues 
[15,19,58–68]. Genetic compartmentalization between tissues has been widely studied [69–78], and 
has also been noted between macrophages and T cells [18,79–81], although recent studies adopting the 
SGA approach suggest that clonal proliferation or amplification within tissues may have 
over-estimated previous measures of genetic diversity identified using bulk or limiting dilution PCR 
methods [82–86]. Earlier studies suggested T-cell associated virus was capable of replicating in 
macrophages in vitro [87]. In a study in which compartmentalized variants in blood monocytes were 
cloned and phenotyped, R5 mac-tropic viruses predominated, although R5X4 dual-tropic viruses were 
also isolated that infected both MDM and CD4+ T cells [88]. Within the CNS, a cross-sectional 
analysis associated compartmentalization with disease stage [89]. An interesting SGA-sequencing 
study of longitudinally-acquired CSF and blood samples provided evidence of independent and 
dynamic sequence variation in the CNS [90]. Viruses 2011, 3  
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Compartmentalized viruses may evolve by stochastic variation within a spatially confined location, 
or as a result of adaptation to the available target cells, microenvironment and immune pressures [91]. 
Macrophages in different tissue sites are extremely heterogeneous [1], and display different levels of 
CD4 and coreceptor expression, responsiveness to activation and most importantly, permissiveness to 
HIV-1 infection [92]. For example, vaginal macrophages are more similar to MDM in phenotype and 
infectibility [93], whereas gut and alveolar macrophages are significantly less permissive [22,93]. It is 
unclear what mediates this heterologous permissiveness, although in the case of the well-characterized 
gut macrophages the restricted phenotype arises at both the entry and post-entry levels, and is 
associated with reduced expression of CD4 and CCR5, and reduced nuclear translocation of NF-B 
[93,94]. The gut macrophage phenotype can be recapitulated in vitro by the application of intestinal 
stromal conditioned media to MDM and is dependent on TGF-, highlighting the critical role of the 
tissue cytokine microenvironment in regulating macrophage permissiveness in vivo [93,94].  
The majority of mac-tropic isolates with high MRC are brain-derived [48]. In the brain the most 
abundant target cells are perivascular macrophages and macrophage-lineage microglial cells, which 
unlike gut macrophages are highly infected despite expressing low levels of CD4 and co-receptors [64]. 
The alternative co-receptor CCR3 can also be used by some brain-derived Envs [95,96]. Moreover, 
host immune pressure from NAbs is contained by the blood-brain barrier [31]. Taken together, these 
data suggest that adaptation to tissue conditions, rather than stochastic variation, is the dominant 
influence in determining the viral tropism of compartmentalized variants [97]. However, the 
differential host immune pressures that may drive adaptation in different compartments remain unknown.  
6. Influence of Recombination 
Recombination occurs frequently during HIV-1 replication by switching of reverse transcriptase 
between heterologous RNA strands, which are present within individual cells as a result of multiple 
infection [98]. It has been suggested, using single fluorescently-tagged viruses, that recombination 
occurs more frequently in macrophages than T cells [99], although this finding has not been 
reproduced in other studies [100].  
In a recent study employing SGA and sequencing of chronic isolates in vivo, inter-compartmental 
recombination events were shown to result in transfer of R5 Env determinants that dramatically altered 
R5 mac-tropism and MRC, conferring brain-like MRC to recombinant lymph node isolates [101]. As 
well as implicating Env as a key determinant of tropism, these data raise the possibility that in later 
infection, recombination events between R5 brain-derived viruses and other non-mac-tropic 
tissue-derived R5 viruses could expand intra-host macrophage infection capability. Estimates of the 
frequency of recombination were approximately 10–15% [101]. The mechanism(s) underpinning the 
necessary precursor events to intra-host recombination (such as inter-compartmental migration of 
cell-free or cell-associated virus, and subsequent multiple-virus infection of cells within the new 
compartment) need to be explored. As an efficient mode of viral dissemination [57], cell-to-cell spread 
more frequently leads to multiple single cell infections [102,103], which has recently been proposed as 
a mechanism permitting intermittent viral replication in T cells in the face of effective combination 
ART [102]. Cell-to-cell transmission may therefore also be implicated in increasing the likelihood of 
recombination events in vivo. Recent data provide evidence of transit of sequences between brain to Viruses 2011, 3  
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periphery, occurring at the meninges [104]. Therefore, the brain may represent a reservoir of 
mac-tropic virus with high MRC, which can emerge in later stages of infection. 
7. Molecular Determinants — Entry 
Comparative studies of amino acid signatures in Env gp120 in high MRC versus non-mac-tropic 
isolates have identified several putative molecular determinants of R5 and X4 tropism for 
macrophages. These studies have predominantly utilized isolates obtained by co-culture with PBMC or 
amplified by PCR (with the inherent caveats described above), although the SGA-sequencing approach 
has been recently employed [101]. In most studies, the env sequence was cloned into pseudoviruses, 
and tropism defined as entry and replication in a single-cycle assay. Multiple single amino acid 
differences in the regions of R5 Env involved in CD4 binding principally distinguish between 
mac-tropic and non-mac-tropic isolates, as do incompletely characterized variations in the length and 
number of potential N-linked glycosylation sites (PNGS) in V1/2 regions of Env. In addition, there are 
some indications of an association between sensitivity to a limited number of CD4 binding site 
(CD4bs) NAbs and R5 mac-tropism/MRC [67,105].  
7.1. CD4 Binding 
Adaptation to efficiently enter cells expressing low surface CD4 has been observed in several 
studies using R5 mac-tropic brain isolates (reviewed in [64]), and R5 mac-tropism and/or MRC was 
shown to correlate with sensitivity to inhibitors of CD4-gp120 interactions [14,61,64,101,105,106], 
indicating that the macrophage tropic phenotype is strongly dependent on Env-CD4 binding affinity 
and/or exposure of the CD4 binding site. Molecular determinants include the N283 substitution in the 
C2 region, which enhances the binding affinity of gp120 to CD4 [107], and loss of the N-linked 
glycosylation site N386 in V4 [63]. N283 and N386D mutagenesis of non-mac-tropic R5 Envs 
conferred increased MRC [63]. N386 alone, or in combination with proximal residue R373 [108] was 
suggested to mediate resistance to the broadly neutralizing CD4bs antibody b12. These molecular 
determinants accounted for around 50% of the enhanced mac-tropism/MRC of the pseudotyped Envs 
tested. Additional determinants on the N-terminal flank of the CD4 binding loop within the CD4bs, 
that influence CD4bs exposure, have also been associated with enhanced macrophage tropism and 
altered sensitivity to the tetrameric soluble (s)CD4-based inhibitor PRO 542 [106]. A single E153G 
substitution within the gp120 V1 loop, distant from the CD4bs, was recently associated with enhanced 
R5 MRC, and was abrogated by the reciprocal mutation G153E [109]. The exact mechanism remains 
uncertain, but it probably involves increased exposure of the CD4bs due to a V1-induced 
conformational change in the V3 loop, which incidentally also conferred increased sensitivity to the 
CCR5 binding antibody 477-52D. Moreover, variations in the V1/V2 region were recently identified as 
conferring mac-tropism to recombinant viruses identified by SGA sequencing [101].  
Although mac-tropic Envs display increased sensitivity to inhibitors of CD4 binding, implicating 
the CD4bs [14,61,64,101,105,106], the relationship between the R5 Env properties of mac-tropism or 
MRC, and neutralization sensitivity to NAbs targeting the CD4bs, is less clear. Originally, Gray and 
colleagues demonstrated an association between R5 mac-tropism/MRC and sensitivity to b12 [14], 
confirmed separately by Dunfee and colleagues [67]. However, by contrast with previous studies, Viruses 2011, 3  
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Dunfee and colleagues did not identify an association between R5 MRC and sensitivity to sCD4 [67]. 
N386D mutagenesis of the R5 reference strains YU2 and JRFL enhanced MRC by 1–2 orders of 
magnitude, and increased sensitivity to b12 by approximately 2-fold [67]. However, not all studies 
confirm the association with b12 sensitivity. For reasons as yet unclear, Brown and colleagues 
identified an inverse association with either b12 or 2G12 sensitivity [101] despite demonstrating a 
clear association between sensitivity to sCD4 and MRC. Variation in mac-tropism also emerged prior 
to autologous NAb responses in the study by Richards and colleagues [31], suggesting that the 
properties of NAb sensitivity and mac-tropism may be distinct, although there appeared to be a 
temporal association between reduced MRC and higher NAb activity in later isolates. Taken as a 
whole, the data are inconclusive with regard to an association between NAb sensitivity and 
mac-tropism or MRC, and more studies are required.  
7.2. Co-Receptor Binding 
Similar to the differential interaction with CD4, variable sensitivity to CCR5 inhibitors has also 
been observed for mac-tropic R5 Envs (reviewed in [64]). Reduced sensitivity to fusion inhibitors of 
chronic, compared to early R5 Env isolates spanning V1-5, was not associated with enhanced MRC 
despite increasing the efficiency of productive infection in cell lines and PBMCs, for reasons which 
are unclear [33]. However, a recent study employing a luciferase reporter system and a panel of R5 env 
sequences identified a correlation between entry efficiency in CCR5
low cell lines with stable CD4 
expression, and MRC, suggesting the mac-tropic Envs could more efficiently use low levels of 
co-receptor [110]. Inhibition by the CCR5 entry inhibitor maraviroc was also reduced in the mac-tropic 
R5 Envs, implying that conformational changes that enhanced R5 binding also impaired small 
molecule inhibition. Duenas-Decamp and colleagues [106] observed V3 loop determinants of R5 
mac-tropism. They suggested that a conformational change in the V3 loop increased exposure of 
the CD4bs.  
Whether enhanced co-receptor binding is linked to the macrophage tropism phenotype for X4 Envs 
has been, until very recently, unexplored. Although the majority of mac-tropic brain-derived Envs are 
R5, some brain isolates can differentially use either CCR5 or CXCR4 for entry into macrophages. 
Non-brain R5X4 viruses, on the other hand, use X4 preferentially for macrophage entry [111]. In an 
elegant mutagenesis study of an unusual brain-derived R5X4 virus it was shown that S306 in V3 
conferred enhanced R5-entry via decreased dependence on the N terminus of CCR5, whereas in 
contrast R306 conferred enhanced X4-entry via decreased dependence on the N-terminus of CXCR4. 
This study provides a putative molecular determinant of co-receptor preference for a mac-tropic R5X4 
envelope [111].  
Recently, promising additional determinants were identified that conferred mac-tropism to more 
unusual X4-using mac-tropic Envs [112]. These included amino-acid variants at position 326 in V3, 
and at positions 261 and 263 within the gp41 interactive region of gp120. The presence of Ile 326 was 
critical for mac-tropism across divergent X4 Envs. These X4 Envs were sensitive to large deletions in 
the N-terminus of the chemokine coreceptor CXCR4, suggesting that co-receptor binding and 
mac-tropism for X4-using viruses are linked.  
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8. Molecular Determinants — Post Entry 
Humans have co-evolved with retroviruses, and some 8% of the human genome (more numerous 
than the protein coding regions) is thought to comprise redundant retroviral elements [113]. There are 
a number of host restriction factors that partially regulate cellular permissiveness to HIV-1 infection 
post-entry, some of which are type I IFN-inducible (e.g., Tetherin/BST-2 and the APOBECs). Those 
relevant to macrophage tropism are reviewed in [22]. The fact that restriction factors are unable to 
prevent ongoing HIV-1 replication in the host indicates that the virus has evolved successful strategies 
to overcome such restrictions, which primarily involve the non-structural accessory proteins of HIV-1, 
such as Vif (targets APOBEC3G) and Vpu (targets tetherin) [114]. Viral infectivity is also associated 
with other regulatory proteins such as Nef and Tat. HIV-1 accessory proteins are the focus of a great 
deal of research, most of which falls out of the scope of this article (reviewed in [114] and [115]). Here 
we discuss specifically the role of the HIV-1 accessory proteins such as Tat, Nef, Vif and Vpu in 
determining MRC. 
8.1. Tat 
The viral trans-activator protein Tat regulates viral gene expression, through interactions with the 
HIV-1 transactivation response element (TAR) RNA [116]. Reduced tat mRNA expression in MDM 
has been shown to correlate with reduction in steady-state R5 virus production [117], which can be 
recovered by the addition of exogenous Tat protein [117]. Alterations of tat expression have been 
linked to changes in the balance of host cellular RNA processing factors, rather than a reduction in tat 
mRNA stability [118]. Truncation mutants of tat (wherein the second coding exon is deleted) have 
highlighted the importance of the second coding exon for MRC in MDM [119] despite preserved 
single-cycle replication of these tat mutants in reporter cell lines, which implies the second coding 
exon may have additional activity in MDM separate from transcriptional activation [119]. In a study of 
LTR sequences, amplified by nested PCR and cloned into luciferase-expressing pseudoviruses from 
patients during progression to AIDS, there was an increase in the in vitro single-cycle transcription 
activity of late stage HIV-1 LTR in various target cells (including MDM) in a subset of patients, 
suggesting the enhanced replication capacity of isolates observed later in disease (see Section 3) may 
be partially mediated by LTR transactivation activity [120]. However, compartmentalization of 
PCR-amplified tat sequences in neural versus lymphoid tissues was not convincingly demonstrated in 
a recent study, and no enhancement of LTR transactivation activity by brain-derived tat sequences in 
patients with HIV-associated dementia (HAD) was observed [121], again suggesting that if tat  is 
important in determining MRC this function may be distinct from LTR transactivation. In keeping with 
this hypothesis, exogenous Tat protein has been shown to enhance MRC through upregulation of the 
IL-7R, leading to enhanced IL-7R signaling in response to IL-7 [122]. Whether this or a similar 
mechanism, rather than LTR transactivation, accounts for the enhancement of MRC by tat remains to 
be conclusively determined. 
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8.2. Vif 
The viral infectivity factor (Vif), as the name suggests, enhances infection. vif-deleted viruses are 
either unable to establish spreading infections in MDM [123,124], or can only sustain very low levels 
of MRC [125]. The activity of Vif appears to be dominated by its targeting of the host restriction factor 
apoplipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G) [126]. 
APOBEC3G is packaged into progeny virions and restricts infectivity by inducing G-to-A 
hypermutations in viral DNA in subsequent rounds of infection (reviewed in [127]). Additional 
non-editing roles for APOBEC3G in regulating viral infectivity have been described [127]. 
Paradoxically, in long-term MDM culture, reduced virion infectivity over time was correlated with a 
reduction in APOBEC3G expression (independent of cytotoxicity), suggesting that Vif may also target 
an additional host factor(s) that may impact on virion infectivity, possibly through impaired 
processing/assembly of Gag capsid [128]. However, few studies have examined specific molecular 
determinants of Vif in relation to macrophage replication.  
8.3. Nef 
The negative factor (Nef) is a 25-27kDa myristoylated protein with multiple functions in mediating 
immune evasion and pathogenicity [114,115] that impact upon in vivo disease progression [129–131]. 
Nef-deleted viruses display impaired MRC in vitro [132,133], and in vivo have been linked to 
long-term non-progression (LTNP), for example in recipients of blood-products contaminated with 
nef-deleted HIV-1 [134]. However, evidence is lacking to relate the pathogenicity of the nef-deleted 
virus with alterations in macrophage tropism phenotype: a longitudinal analysis of R5 blood isolates 
(PBMC-isolated) in one long-term survivor who eventually progressed to AIDS did not demonstrate an 
increase in the low level of MRC during disease progression [135].  
To examine the role of nef in MRC, a mutagenesis study was conducted using the R5 macrophage-
tropic reference strain SF162 [136]. Deletion of nef resulted in delayed replication kinetics and reduced 
MRC, in keeping with previous data. Not surprisingly, significant inter-donor variation in MRC was 
observed, but there was a donor-dependent association between reduced MRC and amino acid 
mutations in the PXXP motif [136]. Interestingly mutations in nef associated with loss of CD4 
down-regulatory function were associated with reduced MRC [136], in contrast to an earlier study in 
cell-lines [137] but in keeping with studies in primary T cells [138] and ex vivo lymphoid tissue [139]. 
CD4 down-regulation of infected cells has been proposed as a mechanism involved both in the 
efficient release of mature budding virions from the host cell membrane [140,141] and in 
enhancing  incorporation of gp160 into the viral envelope [142]. Recent data indicate that HIV-1 
virions in  infected macrophages may bud from a plasma membrane-bound, surface-connected 
“quasi-intracellular” compartment [143–145], suggesting that these mechanisms of CD4 down-regulation 
could be involved in efficient Nef-mediated virus particle release from macrophages. But whilst 
compartmentalization of nef sequences amplified by PCR from neural and blood/lymphoid tissue was 
observed in a recent study in patients with HIV-associated dementia [146], the CD4 down-regulation 
activity of these nef sequences was conserved in both CNS and blood/lymphoid sequences, despite 
clearly distinct mac-tropism [146]. Molecular sequence determinants of MRC in nef were not assessed. Viruses 2011, 3  
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This study and others described above suggest that determinants of CD4 down-regulation may not be 
causally associated in vivo with the macrophage tropism phenotype. Multiple additional functions of 
nef unrelated to MRC may impact pathogenesis [114]. However, in a recent systematic analysis of 
nef-mutations in long-term non-progressors, no consistent molecular signatures were associated with 
LTNP, and variation in nef  was suggestive of rapid sequence evolution rather than deterministic 
mutations favoring attenuated pathogenicity [147]. Further work is required to establish whether the 
well-established molecular determinants of nef functional activity are linked to the macrophage 
tropism phenotype, and to identify specific molecular determinants in nef mediating MRC.  
8.4. Vpu 
HIV-1 viral protein U (Vpu) is a 16kDa protein produced late in the viral replication cycle. The two 
main functions of Vpu are to counteract the host type-1 IFN-induced restriction factor tetherin/BST-2 
to allow viral particle release [148,149] and to degrade intracellular CD4 [114]. Viruses deleted for vpu 
demonstrate low MRC in macrophages [150], which has been associated with increased tetherin/BST-2 
expression and reduced particle release [151]. Counteraction of tetherin is more important for in vitro 
replication in MDM than in lymphocytes or in ex vivo lymphoid tissues [151]. Interestingly, some R5 
isolates with high MRC (e.g., AD8 and YU-2) have start codon mutations in vpu, which were 
previously believed to be redundant and could perhaps be compensated by Env [152], however a study 
of chimeric vpu-deleted viruses expressing YU-2 and AD8 Envs, which had low MRC in vitro, 
suggested Env cannot overcome the loss of Vpu [153]. In addition, a role for vpu in reducing virus 
particle release independent of tetherin downregulation in some cell-lines (but not macrophages) has 
been identified [154]. There is no current satisfactory explanation for the curious paradox of high 
MRC isolates with start codon mutations in vpu, but it is tempting to speculate on a more complex role 
for tetherin in efficient macrophage replication.  
8.5. Vpr/Vpx 
The lentiviral accessory viral proteins R and X (Vpr and Vpx, which have a common genetic origin) 
are also involved in determining tropism for macrophages. The role of Vpr/Vpx has been recently 
reviewed [155], but recent progress warrants acknowledgement here. Vpr is unique to HIV-1, and 
functions by triggering G2 cell cycle arrest and regulating the nuclear transport of the pre-integration 
complex. Deletion of Vpr reduces MRC in vitro, although additional roles are also proposed for Vpr, 
and its in vivo relevance is unclear [155]. Vpx is present in HIV-2 and some SIV strains, but not 
HIV-1, and is indispensable for replication in myeloid cells such as macrophages and dendritic 
cells [155]. When packaged with HIV-1, Vpx also enhances HIV-1 mac-tropism [156,157]. Recent 
studies have identified a host SAM-domain HD-domain containing protein 1 (SAMHD1) as a target 
for Vpx-mediated proteosomal degradation, which overcomes a post-entry block to reverse 
transcription in myeloid cells [158,159]. SAMHD1 [158], like the exonuclease TREX1 [160] may be 
responsible for innate sensing of viral DNA, and viral targeting of SAMHD1 may possibly contribute 
to viral innate immune evasion, although this has not been specifically addressed. Since multiple 
post-entry restriction factors operate in macrophages [22] it is highly probable that many other 
molecular determinants of mac-tropism have yet to be identified.  Viruses 2011, 3  
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9. Conclusion 
Here we have reviewed recent studies concerning viral factors that modulate the macrophage 
tropism phenotype of HIV-1 (see Figure 1). We continue to have an incomplete understanding of the 
viral determinants of tropism for this important target cell, such as which host and virus factors drive 
the apparent compartmentalization of isolates between brain and other tissues, and what molecular 
mechanisms confer efficient HIV-1 replication post-entry. It should also be acknowledged that to date, 
most data on tropism phenotype comes from in vitro assays using MDM, which may not be 
representative of certain tissue macrophages in terms of permissiveness to viral infection. However, 
significant progress has been made, particularly regarding putative amino-acid changes determining 
the CD4 binding efficiency of R5 Envs. Moreover, improved sequencing techniques will allow a 
systematic characterization of the biological phenotype of clinically-relevant transmitted and early 
infection viruses, and should allow questions to be addressed regarding the mediators of tropism 
evolution and its role in disease pathogenesis. More work is required to delineate specific molecular 
determinants of macrophage replication subsequent to viral entry.  
Figure 1. Determinants of macrophage tropism (mac-tropism) and macrophage replication 
capacity (MRC). Theoretical schematic representation of the interacting spectrum of HIV 
permissiveness between different tissues (from low to high on y-axis), and tropism of 
isolates from various stages of infection (from low to high on the x-axis), in determining 
mac-tropism and macrophage replication capacity (MRC) of isolates from various tissues. 
A linear relationship is entirely speculative, as indicated by the dotted line. The key 
molecular determinants of mac-tropism concern receptor-binding efficiency (both CD4 and 
chemokine co-receptor), whilst post-entry the accessory proteins (e.g., Vif, Nef, Vpu, etc.) 
mediate MRC. AIDS = acquired immunodeficiency syndrome. 
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